Liquid Biopsies: Optimization and Sample Quality Controls for ctDNA Measurements
|
Niels Pallisgaard Sjællands Universitetshospital Roskilde, Denmark |
Abstract
It is expected that liquid biopsies with detection and measurement of circulating tumor DNA (ctDNA) in cancer patients will be in clinical routine use in a near future. However, to accomplish this, there is a need for an optimization of all the steps from sampling to report as well as a national or international standardization. Focus in this presentation will be the pre-analytical steps including sampling tubes, plasma isolation and purification (yield, degree of single stranded DNA, Proteinase K carryover and elution volume). In addition to the general workflow, controls to qualify individual samples for use will be discussed, including use of spike-in, measurement of contaminating lymphocyte DNA and DNA fragmentation.
| Back to GQ2023 session page | Back to GQ2023 overview page |
